Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A recent Yahoo Finance item points to a possible acquisition-related expansion of Eli Lilly’s pain portfolio, but does not disclose deal terms in the published recap.
THE APEX TIMES
THE APEX TIMES
Eli Lilly shares moved as Donald Trump spotlighted a new “state-of-the-art” facility and said it would create more than 1,000 jobs.
THE APEX TIMES
A market outlook highlighted by Yahoo Finance projects global sales for Eli Lilly reaching $137 billion in 2032, driven primarily by its obesity and weight-loss portfolio.
THE APEX TIMES
Illumina expanded its board by one seat and appointed Eli Lilly’s Daniel M. Skovronsky, a move that outlines how major drug developers are positioning themselves around the genomics tools they rely on.
THE APEX TIMES
The Hong Kong-listed biotech Abbisko Therapeutics says it has entered a strategic research collaboration and license agreement with Eli Lilly, deepening a partnership that could shape future drug development and IP rights. Key commercial and clinical details were not disclosed in the announcement cited by Yahoo Finance.
THE APEX TIMES
In an interview published Tuesday, Eli Lilly’s chief executive argued that GLP-1 medicines are likely to reshape how the country treats obesity and chronic disease, even as questions remain about cost, access, and long-term uptake.
THE APEX TIMES
In a discussion published by Yahoo Finance, Eli Lilly’s chief executive, Dave Ricks, laid out his view of how drugmakers can navigate the industry’s stop-start pattern of blockbuster launches and subsequent declines, as innovation cycles, pricing pressure, and competition reshape earnings trajectories.
THE APEX TIMES
A market report says Eli Lilly received FDA permission for one patient to receive retatrutide, an experimental treatment for obesity, underscoring how regulators can allow limited access outside standard clinical timelines.
THE APEX TIMES
A June 23 market commentary framed the current competition for investor dollars between Eli Lilly (LLY) and Viking Therapeutics, arguing the expanding GLP-1 market could reward companies with the strongest prospects.
